Wermelskirchen, Germany

Jürgen Scherkenbeck

This inventor holds 1 USPTO granted patent. Top assignee: Bayer Animal Health Gmbh. Active years: 2010.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Jürgen Scherkenbeck. Retrieved from https://idiyas.com/inventor/jürgen-scherkenbeck

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile


Average Co-Inventor Count = 5.0

ph-index = 1


Company Filing History:


Years Active: 2010

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Jürgen Scherkenbeck: Innovator in Endoparasiticides

Introduction

Jürgen Scherkenbeck is a notable inventor based in Wermelskirchen, Germany. He has made significant contributions to the field of veterinary medicine, particularly in the development of endoparasiticides.

Latest Patents

Scherkenbeck holds a patent for "Didepsipeptide-based endoparasiticides, new didepsipeptides and process for preparing the same." This invention relates to the use of didepsipeptides of the general formula (I) and their salts, showcasing his innovative approach to combating parasitic infections in animals.

Career Highlights

He is currently associated with Bayer Animal Health GmbH, where he applies his expertise in developing effective solutions for animal health. His work has been instrumental in advancing the company's product offerings in the veterinary sector.

Collaborations

Scherkenbeck has collaborated with notable colleagues such as Peter Jeschke and Andrew Plant, contributing to a dynamic team focused on innovation in animal health.

Conclusion

Jürgen Scherkenbeck's contributions to the field of veterinary medicine through his patent and work at Bayer Animal Health GmbH highlight his role as a key innovator in the development of effective endoparasiticides.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…